Subscribe 

Good Morning.

We've all had that patient.

Part 1 gave you the science. Part 2 gave you the workflow. Part 3 gives you the documentation that makes phenotype-aware practice defensible — and the language that makes your conversations with sleep medicine partners professional rather than awkward.

Clinical reasoning matters only when it appears in your chart, in your patient's consent form, and in the letter you send when a case needs to be co-managed. Without that paperwork, every escalation appears to be a treatment failure. With it, every escalation looks like the plan is working exactly as designed.

Key Takeaways

30-second version:

• Phenotype-aware consent reframes "treatment failure" as planned escalation. Patients who hear about the possibility of augmentation at the consent visit accept it as care rather than as the appliance failing them.

• Co-management referral letters get responses when they're specific. Lead with the phenotype assessment, attach the data, and ask one clear question.

• Escalation has trigger points. Define them before you titrate, not after. Three thresholds: residual AHI after maximal comfortable advancement, hypoxic burden, and patient-reported outcomes.

• Documentation protects the practice. Clear expectations protect the patient. Both are the quietest success drivers in dental sleep medicine.

• If you have a sleep medicine colleague you want to bring into closer collaboration, this is the issue to share with them.

5-minute read👇

The Phenotype-Aware Consent

Standard OAT consent forms cover the mechanical risks — TMJ discomfort, tooth movement, occlusal changes, and salivary shifts. What most don't cover is the conversation about therapeutic expectations. That's where most "treatment failures" actually originate.

A patient who hears "this appliance will fix your sleep apnea" and then sees a residual AHI of 40% feels misled. A patient who hears "your sleep study shows an anatomical contribution plus an arousal-threshold contribution — the appliance will address the structural piece, and we may need to add a sleep medicine consult for the rest" feels informed. Same outcome, completely different experience.

Phenotype-aware consent adds three sections to your existing OAT consent:

1. Phenotype assessment disclosure. A single paragraph stating which PALM traits you've identified from the patient's existing sleep study, and what each contributes. You're not diagnosing — you're documenting clinical observations and their implications for OAT outcomes.

2. Expected response range, tied to phenotype. Pure anatomical with positional dominance: 70–85% AHI reduction is realistic. Mixed phenotype with arousal-threshold contribution: 30–50% AHI reduction with appliance alone, requiring augmentation for therapeutic response. Be honest about the math.

3. Pre-authorized augmentation plan. If we don't reach our target AHI with optimized OAT alone, here's what comes next: nasal protocol, positional adjuncts, a referral for myofunctional therapy, and/or a sleep medicine consultation for pharmacologic adjuncts. Patient signs acknowledging this is the plan from the start — not a fallback when things "fail."

The legal benefit is real: if a patient later claims "the appliance didn't work, and you didn't tell me it might not," the chart shows otherwise. The clinical benefit is bigger: you stop framing augmentation as a fallback and start framing it as care.

The Co-Management Referral Letter

Most referral letters get filed and ignored. The few that get acted on share three traits:

They lead with the question, not the history. The sleep physician doesn't need a recap of the patient's snoring story; they need to know what you're asking them to do.

They include the data, not just the conclusion. Attach the baseline PSG/HST, the titration log, and the post-titration response data. Don't make the sleep physician request records.

They demonstrate that the dental work is already done. Documenting maximum comfortable advancement, confirming OAT compliance, and showing nasal patency has been addressed signals you've done your part — now you're asking for the medical piece.

Template, four short paragraphs:

That letter takes four minutes once you have the template, and it gets responded to. Compare to the standard "please evaluate" referral that queues behind sixty others.

The Escalation Decision Tree

When titration alone isn't getting you there, the escalation pathway has trigger points — defined thresholds that move a case from "keep titrating" to "augment within dental scope" to "co-manage."

Trigger 1 — Residual AHI after maximal comfortable advancement:

• AHI <5 with symptom resolution → goal achieved; surveillance schedule

• AHI 5–15 with symptom resolution → consider stable; surveillance with annual reassessment

• AHI 5–15 with persistent symptoms → augment within dental scope (positional, nasal Tier 2/3, myofunctional referral)

• AHI >15 regardless of symptoms → escalate to co-management

Trigger 2 — Hypoxic burden, regardless of AHI:

• Time below SpO₂ 90% exceeds 5% of total sleep time → escalate, even with acceptable AHI

• ODI >15 with AHI <15 → suspect loop gain contribution; refer for medical workup

Trigger 3 — Patient-reported outcomes:

• ESS unchanged or worsening at 3 months → reassess phenotype, audit nasal patency, consider co-management

• Bed partner reports persistent witnessed apnea → escalate regardless of AHI

• New cardiovascular or metabolic findings on annual physical → escalate

The decision tree isn't complicated. What's hard is having the discipline to apply it consistently — and the documentation to defend it later.

CLINICAL CORNER

The Series in One Page

For your reference, the entire three-part framework collapsed onto a single workflow:

At consultation:

1. Review the existing sleep study with the four-metric phenotype lens

2. Document primary + contributing phenotypes in the chart

3. Discuss phenotype-aware expectations with the patient

4. Obtain phenotype-aware consent

5. Confirm and address nasal patency (Tier 1 minimum)

At titration:

1. Advance to the maximum comfortable position

2. Document compliance, symptoms, and side effects

3. Order titration outcome study (HST or PSG)

4. Apply Trigger 1, 2, and 3 thresholds

At escalation:

1. Augment within dental scope (positional, nasal Tier 2/3, myofunctional)

2. Co-management referral letter to sleep medicine (template above)

3. ENT referral if structural nasal pathology persists

4. DISE consideration before hypoglossal nerve stimulation

That's it. Phenotype-aware dental sleep medicine in nineteen lines.

Want the printable templates?

The phenotype-aware consent form, the co-management referral letter, and the escalation decision tree from this issue are bundled as a single printable PDF — [Click here for the Phenotype-Aware OAT Documentation Bundle →]. Five pages, fillable consent with checkboxes and signature blocks, a copy-paste-ready referral letter, and a color-coded decision tree. Customize the phenotype language to your patient population, drop in your practice letterhead, and put them to work this week.

A reminder that's worth repeating: review the consent form with your malpractice carrier and state dental board before adopting it in practice. The bundle is a clinical reference tool, not a turnkey legal document.

A note on this issue's sponsor: More Than Teeth is sponsored in part by Xlear, a Utah-based company whose xylitol-based saline nasal sprays we use as part of our Tier 1 conservative nasal protocol at Advanced Dental Care. Xylitol's mucosal benefits make it a clinically meaningful upgrade over plain saline for patients dealing with chronic congestion and mouth breathing. We'll cover product-level recommendations in Issue 2. 

COACH CATHY'S TAKE

 By Cathy Bennett, MS, NBCHWC

Mike came home last week with a patient quote that stopped him: "So this isn't a backup plan. This is the plan." That sentence is the entire reason we wrote this series.

For most of dental sleep medicine's history, augmentation has been framed as what happens when the appliance "doesn't work." The patient returns with a residual AHI of 18, and the conversation becomes damage control — what went wrong, what we missed, who to refer to next. Patients feel disappointed. Providers feel defensive. Outcomes get abandoned.

Phenotype-aware care flips that conversation entirely. At the consent visit, Mike doesn't tell patients, "If this appliance fails, we'll try other things." He tells them, "Your sleep study suggests two contributors — the appliance addresses one, and here's the plan for the other." There is no failure to discuss because no failure is built into the design. There's a plan, the plan has steps, and every step is care.

The provider's job is to use language that matches the truth — at the consent visit, in the referral letter, in the escalation conversation. The language shapes how patients feel about their treatment, and how patients feel shapes whether they show up for the next step.

If you take one thing from this three-part series, take this: stop calling it treatment failure. There's only the plan, working as designed.

Closing the Series

Three issues, one framework: phenotype-aware dental sleep medicine.

Issue 1 made the case for why one-size-fits-all OAT fails one in three patients. Issue 2 gave you the workflow for matching therapy to phenotype. Issue 3 gave you the paperwork that makes the workflow defensible.

If you've made it this far, you've done more clinical reading than most dental sleep practitioners do in a year. The next step is implementation — pull one OAT case from your schedule this week, apply the four-metric PSG lens, draft the phenotype-aware consent, and document everything. The framework only matters when it lives in your charts.

If this series helped you, the most valuable thing you can do is share Issue 3 with a sleep medicine colleague. The conversations that follow are how dental sleep medicine moves from "the alternative for CPAP failures" to "the right first-line treatment for the right phenotype."

That's the whole game.

REFERENCES

1. REFERENCES

   1. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea: identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013;188(8):996-1004. https://doi.org/10.1164/rccm.201303-0448OC

   2. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;11(7):773-827. https://doi.org/10.5664/jcsm.4858

   3. American Academy of Dental Sleep Medicine. Dental sleep medicine standards for screening, treating, and management of sleep-related breathing disorders in adults using oral appliance therapy. J Dent Sleep Med. 2025;12(2). https://aadsm.org/journal/special_article_1_issue_122.php

   4. Camañes-Gonzalvo S, Bellot-Arcís C, Marco-Pitarch R, et al. Comparison of the phenotypic characteristics between responders and non-responders to obstructive sleep apnea treatment using mandibular advancement devices in adult patients: systematic review and meta-analysis. Sleep Med Rev. 2022;64:101644. https://doi.org/10.1016/j.smrv.2022.101644

   5. Sutherland K, Vanderveken OM, Tsuda H, et al. Oral appliance treatment for obstructive sleep apnea: an update. J Clin Sleep Med. 2014;10(2):215-227. https://doi.org/10.5664/jcsm.3460

      Click here for related podcast topics.

Until next series,
Dr. Michael & Cathy Bennett
More Than Teeth | A Mission for Generational Health